Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II booster study of two formulations of GSK pneumococcal protein candidate vaccine in previously primed healthy young adults
2009-011022-33Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, double-blind trial of GSK2189242A in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: Occurrence of vaccine-related and grade 3 solicited adverse events. Started Apr 2009; status: completed.
02
Drugs
GSK2189242A
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2009-011022-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011022-33.